Skip to main content
Springer logoLink to Springer
. 2020 Nov 12;15(6):807. doi: 10.1007/s11523-020-00772-4

Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

Dietger Niederwieser 1,2,3,, Caroline Hamm 4, Patrick Cobb 5, Mindy Mo 6, Cecily Forsyth 7, Alessandra Tucci 8, Vladimir Hanes 6, Vincent Delwail 9, Roman Hajek 10, David Chien 6
PMCID: PMC7701060  PMID: 33180232

Correction to: Targeted Oncology (2020) 15:599–611 10.1007/s11523-020-00748-4

Page 608, 4 Discussion, right column, second paragraph: The sentence, which previously read:

“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 0.3 to 11.2%)”.

should read:

“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B-cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 9.3 to 11.2%)”.

The original article has been updated.


Articles from Targeted Oncology are provided here courtesy of Springer

RESOURCES